These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30526517)

  • 1. Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.
    Cerveira N; Ferreira RB; Bizarro S; Correia C; Torres L; Lisboa S; Vieira J; Santos R; Campilho F; Pinho Vaz C; Leite L; Teixeira MR; Campos A
    BMC Cancer; 2018 Dec; 18(1):1229. PubMed ID: 30526517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical activity of ponatinib in one patient with chronic myeloid leukemia in chronic phase with e19a2 transcript and T315I mutation.
    Ferri CA; Bianchini M; Bengió RM; Moiraghi EB; Gonzalez MS; Noriega MF; Larripa IB
    Eur J Haematol; 2015 Mar; 94(3):270-2. PubMed ID: 24766374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
    Parker WT; Yeung DT; Yeoman AL; Altamura HK; Jamison BA; Field CR; Hodgson JG; Lustgarten S; Rivera VM; Hughes TP; Branford S
    Blood; 2016 Apr; 127(15):1870-80. PubMed ID: 26773037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T315I mutation exerts a dismal prognosis on adult BCR-ABL1-positive acute lymphoblastic leukemia, and salvage therapy with ponatinib or CAR-T cell and bridging to allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Ting S; Mixue X; Lixia Z; Xueying L; Wanzhuo X; Xiujin Y
    Ann Hematol; 2020 Apr; 99(4):829-834. PubMed ID: 32107574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.
    Sasaki H; Mitani S; Kusumoto S; Marumo Y; Asano A; Yoshida T; Narita T; Ito A; Yano H; Ri M; Ishida T; Komatsu H; Iida S
    Int J Hematol; 2019 Jul; 110(1):119-123. PubMed ID: 30879266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponatinib therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with T315I mutation after Allo-HSCT.
    He JB; Zhang X; Guo ZW; Liu MM; Xu N; Huang F; Fan ZP; Xuan L; Deng L; Lin SH; Xu J; Sun J; Liu QF
    Int J Cancer; 2020 Aug; 147(4):1071-1077. PubMed ID: 31785158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
    Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
    Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical characteristics of chronic myeloid leukemia with T315I mutation and the efficacy of ponatinib].
    Chen C; Xu N; Jiang X; Wu W; Zhou X; Liu L; Huang J; Yin C; Cao R; Liao L; Xu D; Zhang Y; Liu Q; Liu X
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Mar; 39(3):364-368. PubMed ID: 31068313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
    Oaxaca DM; Yang-Reid SA; Ross JA; Rodriguez G; Staniswalis JG; Kirken RA
    Tumour Biol; 2016 Sep; 37(9):12643-12654. PubMed ID: 27444277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis.
    Mela Osorio MJ; Moiraghi B; Osycka MV; Pavlovsky MA; Varela AI; Bendek Del Prete GE; Tosin MF; Pérez MA; Riva ME; Berrios RR; Fernández I; Sackmann Massa F; Giere I; Sighel C; Pavlovsky C
    Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):158-164. PubMed ID: 37973457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR-ABL1 compound mutations drive ponatinib resistance.
    Cancer Discov; 2014 Nov; 4(11):OF13. PubMed ID: 25367954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ponatinib Induces a Persistent Molecular Response and Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia with a T315I Mutation following Early Relapse after Allogeneic Transplant.
    Renzi D; Marchesi F; De Angelis G; Elia L; Salvatorelli E; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Papa E; Canfora M; Arcese W; Mengarelli A;
    Chemotherapy; 2017; 62(1):58-61. PubMed ID: 27618144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
    Sazawal S; Chikkara S; Singh K; Chaubey R; Chandra D; Mishra P; Mahapatra M; Seth T; Saxena R
    Ann Diagn Pathol; 2017 Apr; 27():24-27. PubMed ID: 28325357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
    Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
    Zhang J; Zhang X; Lu Y; Jiao J; Chen Y; Lin D
    Clin Lab; 2018 Jan; 64(1):193-196. PubMed ID: 29479884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia.
    Basak G; Torosian T; Snarski E; Niesiobedzka J; Majewski M; Gronkowska A; Urbanowska E; Jedrzejczak W
    Ann Transplant; 2010; 15(2):68-70. PubMed ID: 20657522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features.
    Tusa I; Cheloni G; Poteti M; Silvano A; Tubita A; Lombardi Z; Gozzini A; Caporale R; Scappini B; Dello Sbarba P; Rovida E
    Target Oncol; 2020 Oct; 15(5):659-671. PubMed ID: 32780298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
    Deininger MW; Hodgson JG; Shah NP; Cortes JE; Kim DW; Nicolini FE; Talpaz M; Baccarani M; Müller MC; Li J; Parker WT; Lustgarten S; Clackson T; Haluska FG; Guilhot F; Kantarjian HM; Soverini S; Hochhaus A; Hughes TP; Rivera VM; Branford S
    Blood; 2016 Feb; 127(6):703-12. PubMed ID: 26603839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ponatinib in childhood Philadelphia chromosome-positive leukaemias: an international registry of childhood chronic myeloid leukaemia study.
    Millot F; Suttorp M; Versluys AB; Kalwak K; Nelken B; Ducassou S; Bertrand Y; Baruchel A
    Eur J Cancer; 2020 Sep; 136():107-112. PubMed ID: 32668374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
    Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
    Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.